DocWire News Editors

DocwireNews

A research team from the University of Illinois at Chicago and Queensland University of Technology of Australia recently created technology that can isolate cancer cells within a patient&rsquo;s blood sample. Separating various types of cells in the blood by size, this microfluidic device could potentially provide rapid and inexpensive liquid biopsies to diagnose and plan treatments of cancers. These researchers&rsquo; findings were recently published in Microsystems &amp; Nanoengineering.&ldquo;This new microfluidics chip lets us separate cancer cells from whole blood or minimally-diluted blood,&rdquo; claimed Ian Papautsky, corresponding author of the paper and the Richard and Loan Hill Professor of Bioengineering in the UIC College of Engineering and corresponding author on the paper. &ldquo;While devices for detecting cancer cells circulating in the blood are becoming available, most are relatively expensive and are out of reach of many research labs or hospitals. Our device is cheap, and doesn&rsquo;t require much specimen preparation or dilution, making it fast and easy to use.&rdquo;<a href="https://proddocwire.wpengine.com/docwire-pick/hem-onc-picks/racial-disparities-cancer-mortality/">READ MORE:&nbsp;American Cancer Society Says Racial Disparities in Cancer Mortality are Declining in the U.S.</a>Isolating individual cancer cells is a challenging, yet essential step in creating a liquid biopsy system using simple blood samples. Creating such a system would eliminate the uncomfortable biopsy procedures currently in place, often using needles or surgery to diagnose the cancer. A liquid biopsy that matched the efficacy of traditional biopsy methods would likely do so at a reduced cost as well. Liquid biopsy procedures could also hold utility in tracking chemotherapy treatments over time, as well as detecting cancers in organs such as the lungs or brain that are challenging to reach.The challenge presents in isolating these cancer cells from the blood samples, being that they are usually present in trace quantities. Many cancers display circulating cells at levels as low as one per 1 billion blood cells. &ldquo;A 7.5-milliliter tube of blood, which is a typical volume for a blood draw, might have ten cancer cells and 35-40 billion blood cells,&rdquo; Papautsky stated. &ldquo;So we are really looking for a needle in a haystack.&rdquo;<a href="https://proddocwire.wpengine.com/docwire-pick/future-of-medicine-picks/urine-test-detecting-organ-rejection-could-replace-invasive-biopsies/">READ MORE:&nbsp;Urine Test Detecting Organ Rejection Could Replace Invasive Biopsies</a>Using an alternative means to traditional cell detection in blood, the researchers decided to employ microfluidic technologies in their model. Such devices use markers to captured targeted cells as they pass by or separate the targeted cells from other cells in the sample by physical properties such as size.Papautsky and his team decided to use the latter of these two detection mechanisms in their device, targeted cell size as the main means of separation. &ldquo;Using size differences to separate cell types within a fluid is much easier than affinity separation which uses &lsquo;sticky&rsquo; tags that capture the right cell type as it goes by,&rdquo; he said. &ldquo;Affinity separation also requires a lot of advanced purification work which size separation techniques don&rsquo;t need.&rdquo;<a href="https://proddocwire.wpengine.com/docwire-pick/a-simple-blood-test-for-melanoma-detection/">READ MORE:&nbsp;A Simple Blood Test for Melanoma Detection?</a>The device they created separates cancer cells as they pass through microchannels formed in plastic, making use of the phenomena known as inertial migration and shear-induced diffusion. Papautsky notes that he and his colleagues are still researching the physics that involve these phenomena and how to best integrate them into the device. In describing the process, he said it &ldquo;separates cells based on tiny differences in size which dictate the cell&rsquo;s attraction to various locations within a column of liquid as it moves.&rdquo;Inserting 10 small-cell-lung cancer cells into 5 milliliter samples of healthy blood, the team was able to recover 93% of the cancer cells using their microfluidic device. Microfluidic devices tested in the past were only able to separate tumor cells from serum samples with recovery rates of 50-80% at best.Papautsky noted that the device is not only extremely efficient and reliable, but that little dilution of the samples is needed as well. &ldquo;Without having to dilute, the time to run samples is shorter and so is preparation time.&rdquo;<blockquote class="twitter-tweet" data-lang="en">
New microfluidics device can detect cancer <a href="https://twitter.com/hashtag/cells?src=hash&amp;ref_src=twsrc%5Etfw">#cells</a> in <a href="https://twitter.com/hashtag/blood?src=hash&amp;ref_src=twsrc%5Etfw">#blood</a> <a href="https://t.co/k9oHspxA13">https://t.co/k9oHspxA13</a>
&mdash; Phys.org (@physorg_com) <a href="https://twitter.com/physorg_com/status/1100129500443090944?ref_src=twsrc%5Etfw">February 25, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Source: <a href="https://www.eurekalert.org/pub_releases/2019-02/uoia-nmd022519.php">EurekAlert</a>

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Microfluidic Device Detects Cancer Cells in Simple Blood Sample

Future of Medicine

A research team from the University of Illinois at Chicago and Queensland University of Technology of Australia recently created technology that can isolate cancer cells ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe